Table 3-1
Changes in five-year observed survival proportions over time by diagnostic group and selected subgroup, ages 0 to 14 at diagnosis, Canada excluding Quebec, 1992-to-1996 period to 2013-to-2017 period — Part 1


Table 3-1
Changes in five-year observed survival proportions over time by diagnostic group and selected subgroup, ages 0 to 14 at diagnosis, Canada excluding Quebec, 1992-to-1996 period to 2013-to-2017 period — Part 1
Table summary
This table displays the results of Changes in five-year observed survival proportions over time by diagnostic group and selected subgroup. The information is grouped by Diagnostic group / subgroup (appearing as row headers), Time period, OSP (%), 1992 to 1996, 2003 to 2007, 2013 to 2017 and 95% CI (appearing as column headers).
Diagnostic group / subgroup Time period
OSP (%) 1992 to 1996 OSP (%) 2003 to 2007 OSP (%) 2013 to 2017
95% CI 95% CI 95% CI
from to from to from to
All groups 77 75 78 83 82 84 84 83 85
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases 78 75 80 87 85 89 88 87 90
a. Lymphoid leukemias 85 83 87 91 89 93 93 92 95
b. Acute myeloid leukemias 48 40 55 72 64 78 65 57 71
c. Chronic myeloproliferative diseases 55Note E: Use with caution 35 71 87Note E: Use with caution 66 96 90 79 95
II. Lymphomas and reticuloendothelial neoplasms 84 80 88 91 88 94 92 89 94
a. Hodgkin lymphomas 90 83 94 99 95 100 99 95 100
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 77 67 84 90 82 94 84 78 89
c. Burkitt lymphoma 92 80 97 88 76 95 94 84 98
d. Miscellaneous lymphoreticular neoplasms Note F: too unreliable to be published Note F: too unreliable to be published Note F: too unreliable to be published 73Note E: Use with caution 50 87 94 88 97
III. CNS and miscellaneous intracranial and intraspinal neoplasms 67 63 70 71 68 75 72 69 75
a. Ependymomas and choroid plexus tumour 46Note E: Use with caution 33 58 66Note E: Use with caution 52 76 78 67 86
b. Astrocytomas 83 79 87 84 79 87 82 78 86
c. Intracranial and intraspinal embryonal tumours 55 47 62 59 51 67 71 64 78
d. Other gliomas 45Note E: Use with caution 34 55 60Note E: Use with caution 49 69 42 33 51
IV. Neuroblastoma and other peripheral nervous cell tumours 65 59 71 79 73 84 84 79 88
a. Neuroblastoma and ganglioneuroblastoma 65 58 71 79 73 84 84 79 88
V. Retinoblastoma 99 93 100 94 84 98 94 85 98
VI. Renal tumours 87 81 91 85 79 90 96 91 98
a. Nephroblastoma and other nonepithelial renal tumours 86 81 91 86 79 90 96 92 98
VII. Hepatic tumours 70Note E: Use with caution 56 81 71Note E: Use with caution 56 81 72Note E: Use with caution 58 82
VIII. Malignant bone tumours 73 65 79 68 60 75 72 64 78
a. Osteosarcomas 66Note E: Use with caution 55 75 70Note E: Use with caution 58 79 65Note E: Use with caution 53 74
c. Ewing tumour and related sarcomas of bone 76Note E: Use with caution 61 86 64Note E: Use with caution 51 74 79Note E: Use with caution 66 87
IX. Soft tissue and other extraosseous sarcomas 70 64 76 68 61 74 70 64 76
a. Rhabdomyosarcomas 67 59 75 63 53 72 69 60 77
d. Other specified soft tissue sarcomas 80Note E: Use with caution 66 88 77Note E: Use with caution 65 86 71Note E: Use with caution 60 80
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 87 79 92 91 84 95 91 85 95
b. Malignant extracranial and extragonadal germ cell tumours 88Note E: Use with caution 66 96 96 76 99 91 75 97
c. Malignant gonadal germ cell tumours 94 83 98 96 83 99 97 83 100
XI. Other malignant epithelial neoplasms and malignant melanomas 86 78 91 94 88 97 92 86 95
b. Thyroid carcinomas 97 83 100 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
f. Other and unspecified carcinomas 77Note E: Use with caution 61 87 83Note E: Use with caution 65 92 88 78 94
XII. Other and unspecified malignant neoplasms 91Note E: Use with caution 74 97 93 82 97 80Note E: Use with caution 55 92
.. not available for a specific reference period
E Use with caution
F too unreliable to be published
Notes: OSP = observed survival proportion; CI = confidence interval; CNS = central nervous system. OSPs for all groups combined were calculated as a weighted average of sex- and diagnostic-group-specific estimates. Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the Canadian Cancer Registry. All estimates are based on invasive behaviour cases only. OSPs for the 2013-to-2017 period were predicted using the period method. The use of caution is suggested in the interpretation of estimates associated with an unrounded standard error > 0.05 and ≤ 0.10.; if > 0.10, estimates were considered too unreliable to be published. Differences in survival over the full period may not equal the sum of differences for the subperiods because of rounding.
Source: Statistics Canada, Canadian Cancer Registry death linked file (1992 to 2017).

More information

ISSN: 1209-1367

Note of appreciation

Canada owes the success of its statistical system to a long-standing partnership between Statistics Canada, the citizens of Canada, its businesses, governments and other institutions. Accurate and timely statistical information could not be produced without their continued co-operation and goodwill.

Standards of service to the public

Statistics Canada is committed to serving its clients in a prompt, reliable and courteous manner. To this end, the Agency has developed standards of service which its employees observe in serving its clients.

Copyright

Published by authority of the Minister responsible for Statistics Canada.

© Her Majesty the Queen in Right of Canada as represented by the Minister of Industry, 2021

All rights reserved. Use of this publication is governed by the Statistics Canada Open Licence Agreement.

Catalogue no. 82-003-X

Frequency: Monthly

Ottawa

Report a problem on this page

Is something not working? Is there information outdated? Can't find what you're looking for?

Please contact us and let us know how we can help you.

Privacy notice

Date modified: